A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer

Andrea Lunardi,Ugo Ala,Mirjam T. Epping,Leonardo Salmena,John G. Clohessy,Kaitlyn A. Webster,Guocan Wang,Roberta Mazzucchelli,Maristella Bianconi,Edward C. Stack,Rosina T. Lis,Akash Patnaik,Lewis C. Cantley,Glenn J. Bubley,Carlos Cordon-Cardo,William L. Gerald,Rodolfo Montironi,Sabina Signoretti,Massimo Loda,Caterina Nardella,Pier Paolo Pandolfi

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer

2013

Pier Paolo Pandolfi and colleagues report that compound loss of Pten with Zbtb7a or Trp53 leads to de novo resistance to androgen deprivation therapy in prostate cancer. Integrative analysis of mouse and human data in a co-clinical approach identified XIAP and SRD5A1 inhibitors as potential therapies for castration-resistant prostate cancer.

Keywords:

Androgen
PTEN
Orchiectomy
XIAP
Genetics
Oncology
SRD5A1
Prostate cancer
Medical genetics
Androgen deprivation therapy
Pharmacology
Internal medicine
Biology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

116

Citations